William Bain

William Bain

Auto-generated profile, based on publicly available information

William Bain

Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh, Pittsburgh, PA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2021 in Science
Verified
Journal Article
Open access
PDF file
KMKevin R. McCarthy
Kevin R. McCarthy
LRLinda J. Rennick
Linda J. Rennick
SNSham Nambulli
Sham Nambulli
LRLindsey R. Robinson-McCarthy
Lindsey R. Robinson-McCarthy
WBWilliam G. Bain
William G. Bain
WWWewee Wewewe
Wewee Wewewe
Eluding detection: Influenza viruses evade immunity initiated by previous infection, which explains recurrent influenza pandemics. Unlike the error-prone RNA-dependent RNA polymerase of influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related viruses contain polymerases with proofreading activity. However, proofreading cannot correct deletions, which during a long-term persistent infection could result in the generation of viruses showing alteration of entire stretches of amino acids and the structures they form. McCarthy et al. identified an evolutionary signature defined by prevalent and recurrent deletions in the spike protein of SARS-CoV-2 at four antigenic sites. Deletion variants show human-to-human transmission of viruses with altered antigenicity. Science , this issue p. 1139

17 March 2021 in Infection and Immunity
Verified
Journal Article
Open access
PDF file
SGShekina Gonzalez-Ferrer
Shekina Gonzalez-Ferrer
HPHernán F. Peñaloza
Hernán F. Peñaloza
JBJames A. Budnick
James A. Budnick
WBWilliam G. Bain
William G. Bain
HNHayley R. Nordstrom
Hayley R. Nordstrom
DTDaria Van Tyne
Daria Van Tyne
Klebsiella pneumoniae are Gram-negative facultative anaerobes that are found within host-associated commensal microbiomes, but they can also cause a wide range of infections that are often difficult to treat. These infections are caused by different pathotypes of K. pneumoniae , called either classical or hypervirulent strains.

8 February 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
YQYanyan Qu
Yanyan Qu
TOTolani Olonisakin
Tolani Olonisakin
WBWilliam Bain
William Bain
JZJill Zupetic
Jill Zupetic
RBRebecca Brown
Rebecca Brown
JLJanet S. Lee
Janet S. Lee
Acute lung injury is characterized by excessive extracellular matrix proteolysis and neutrophilic inflammation. A major risk factor for lung injury is bacterial pneumonia. However, host factors that protect against pathogen-induced and host-sustained proteolytic injury following infection are poorly understood. Pseudomonas aeruginosa (PA) is a major cause of nosocomial pneumonia and secretes proteases to amplify tissue injury. We show that thrombospondin-1 (TSP-1), a matricellular glycoprotein released during inflammation, dose-dependently inhibits PA metalloendoprotease LasB, a virulence factor. TSP-1–deficient ( Thbs1 –/– ) mice show reduced survival, impaired host defense, and increased lung permeability with exaggerated neutrophil activation following acute intrapulmonary PA infection. Administration of TSP-1 from platelets corrects the impaired host defense and aberrant injury in Thbs1 –/– mice. Although TSP-1 is cleaved into 2 fragments by PA, TSP-1 substantially inhibits Pseudomonas elastolytic activity. Administration of LasB inhibitor, genetic disabling of the PA type II secretion system, or functional deletion of LasB improves host defense and neutrophilic inflammation in mice. Moreover, TSP-1 provides an additional line of defense by directly subduing host-derived proteolysis, with dose-dependent inhibition of neutrophil elastase from airway neutrophils of mechanically ventilated critically ill patients. Thus, a host matricellular protein provides dual levels of protection against pathogen-initiated and host-sustained proteolytic injury following microbial trigger.

3 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
GKGeorgios D. Kitsios
Georgios D. Kitsios
KSKhaled Sayed
Khaled Sayed
AFAdam Fitch
Adam Fitch
HYHaopu Yang
Haopu Yang
NBNoel Britton
Noel Britton
BMBryan J. McVerry
Bryan J. McVerry
Critical illness can significantly alter the composition and function of the human microbiome, but few studies have examined these changes over time. Here, we conduct a comprehensive analysis of the oral, lung, and gut microbiota in 479 mechanically ventilated patients (223 females, 256 males) with acute respiratory failure. We use advanced DNA sequencing technologies, including Illumina amplicon sequencing (utilizing 16S and ITS rRNA genes for bacteria and fungi, respectively, in all sample types) and Nanopore metagenomics for lung microbiota. Our results reveal a progressive dysbiosis in all three body compartments, characterized by a reduction in microbial diversity, a decrease in beneficial anaerobes, and an increase in pathogens. We find that clinical factors, such as chronic obstructive pulmonary disease, immunosuppression, and antibiotic exposure, are associated with specific patterns of dysbiosis. Interestingly, unsupervised clustering of lung microbiota diversity and composition by 16S independently predicted survival and performed better than traditional clinical and host-response predictors. These observations are validated in two separate cohorts of COVID-19 patients, highlighting the potential of lung microbiota as valuable prognostic biomarkers in critical care. Understanding these microbiome changes during critical illness points to new opportunities for microbiota-targeted precision medicine interventions.

19 November 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
KMKevin R. McCarthy
Kevin R. McCarthy
LRLinda J. Rennick
Linda J. Rennick
SNSham Nambulli
Sham Nambulli
LRLindsey R. Robinson-McCarthy
Lindsey R. Robinson-McCarthy
WBWilliam G. Bain
William G. Bain
WWWewee Wewewe
Wewee Wewewe
Zoonotic pandemics, like that caused by SARS-CoV-2, can follow the spillover of animal viruses into highly susceptible human populations. Their descendants have adapted to the human host and evolved to evade immune pressure. Coronaviruses acquire substitutions more slowly than other RNA viruses, due to a proofreading polymerase. In the spike glycoprotein, we find recurrent deletions overcome this slow substitution rate. Deletion variants arise in diverse genetic and geographic backgrounds, transmit efficiently, and are present in novel lineages, including those of current global concern. They frequently occupy recurrent deletion regions (RDRs), which map to defined antibody epitopes. Deletions in RDRs confer resistance to neutralizing antibodies. By altering stretches of amino acids, deletions appear to accelerate SARS-CoV-2 antigenic evolution and may, more generally, drive adaptive evolution.

5 June 2020 in Current Protocols in Cytometry
Verified
Journal Article
Open access
WBWilliam Bain
William Bain
JLJanet S. Lee
Janet S. Lee
AWAlan Watson
Alan Watson
MSMolly S. Stitt‐Fischer
Molly S. Stitt‐Fischer
SARS‐CoV‐2 is a novel coronavirus that causes the acute respiratory disease—Coronavirus disease 2019 (COVID‐19)—which has led to a global health crisis. Currently, no prophylactics or therapies exist to control virus spread or mitigate the disease. Thus, the risk of infection for physicians and scientists is high, requiring work to be conducted in Biosafety Level‐3 (BSL‐3) facilities if virus will be isolated or propagated. However, inactivation of the virus can enable safe handling at a reduced biosafety level, making samples accessible to a diverse array of institutions and investigators. Institutions of all types have an immediate need for guidelines that outline safe collection, handling, and inactivation of samples suspected to contain active virus. Here we provide a practical guide for physicians and researchers wishing to work with materials from patients who are COVID‐19 positive or suspected positive. © 2020 Wiley Periodicals LLC.Basic Protocol 1: Practical guidelines for the safe collection and handling of specimens collected from COVID‐19 and suspected COVID‐19 patientsBasic Protocol 2: Inactivating SARS‐CoV‐2